An AI model may help identify patients with myelofibrosis at high risk of early death after transplant, according to an ...

Although there are several therapies available to treat myelofibrosis, the only curative option remains allogeneic-hematopoietic cell transplantation (allo-HCT), when healthy stem cells from a ...

Machine learning model improves transplant ... with myelofibrosis. Mosquera explained the importance of using data-driven approaches to address unmet medical needs in hematology, particularly in ...

FRIDAY, April 4, 2025 (HealthDay News) -- For patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation (allo-HCT), machine learning (ML) enhances risk stratification ...

Although there are several therapies available to treat myelofibrosis, the only curative option remains allogeneic-hematopoietic cell transplantation (allo-HCT), when healthy stem cells from a ...

before transplantation and the overall survival (OS) of patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). The median follow-up time among the patients was 19.7 months ...

Research has shown that autologous hematopoietic stem cell transplantation is an effective treatment for MS. At 2 years and 4 years post-transplant, relapse-free survival rates were 94% and 89% ...

Hematopoietic stem cell transplantation (HSCT) plays a significant therapeutic role in treating these patients. Theodore B. Moore, MD, Director, UCLA Pediatric Bone Marrow Transplant Program ...

Hany Elmariah, MD, discusses incorporating fedratinib as maintenance therapy in the posttransplant setting to prevent relapse of MPNs and graft-vs-host disease.

in allogeneic hematopoietic stem cell transplantation (allo-HSCT), highlighting the role of the recipient's circadian rhythms. The team was led by Prof. Zhan Cheng from the University of Science ...